169 related articles for article (PubMed ID: 2557298)
1. Activity of batracylin (NSC-320846) against solid tumors of mice.
Mucci-LoRusso P; Polin L; Bissery MC; Valeriote F; Plowman J; Luk GD; Corbett TH
Invest New Drugs; 1989 Nov; 7(4):295-306. PubMed ID: 2557298
[TBL] [Abstract][Full Text] [Related]
2. Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice.
Mucci-LoRusso P; Polin L; Biernat LA; Valeriote FA; Corbett TH
Invest New Drugs; 1990 Aug; 8(3):253-61. PubMed ID: 2177044
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P; Wozniak AJ; Polin L; Capps D; Leopold WR; Werbel LM; Biernat L; Dan ME; Corbett TH
Cancer Res; 1990 Aug; 50(16):4900-5. PubMed ID: 2165850
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor activity of batracylin (NSC 320846).
Plowman J; Paull KD; Atassi G; Harrison SD; Dykes DJ; Kabbe HJ; Narayanan VL; Yoder OC
Invest New Drugs; 1988 Sep; 6(3):147-53. PubMed ID: 3192381
[TBL] [Abstract][Full Text] [Related]
5. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.
Corbett TH; Bissery MC; Wozniak A; Plowman J; Polin L; Tapazoglou E; Dieckman J; Valeriote F
Invest New Drugs; 1986; 4(3):207-20. PubMed ID: 3546183
[TBL] [Abstract][Full Text] [Related]
6. A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
Atassi G; Dumont P; Kabbe HJ; Yoder O
Drugs Exp Clin Res; 1988; 14(9):571-4. PubMed ID: 3229319
[TBL] [Abstract][Full Text] [Related]
7. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
Bissery MC; Nguyen CH; Bisagni E; Vrignaud P; Lavelle F
Invest New Drugs; 1993 Nov; 11(4):263-77. PubMed ID: 8157469
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of DMP 840 against mouse and human solid tumor models.
LoRusso P; Demchik L; Dan M; Polin L; Gross JL; Corbett TH
Invest New Drugs; 1995; 13(3):195-203. PubMed ID: 8729946
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169.
Corbett TH; White K; Polin L; Kushner J; Paluch J; Shih C; Grossman CS
Invest New Drugs; 2003 Feb; 21(1):33-45. PubMed ID: 12795528
[TBL] [Abstract][Full Text] [Related]
11. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
12. Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
Dexter DL; Hesson DP; Ardecky RJ; Rao GV; Tippett DL; Dusak BA; Paull KD; Plowman J; DeLarco BM; Narayanan VL
Cancer Res; 1985 Nov; 45(11 Pt 1):5563-8. PubMed ID: 4053030
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
14. Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat.
Ames MM; Mathiesen DA; Reid JM
Invest New Drugs; 1991 Aug; 9(3):219-25. PubMed ID: 1783521
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
Goldin A; Venditti JM; Geran R
Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
20. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
Sirotnak FM; Otter GM; Schmid FA
Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
